Cognitive impairment and associations with structural brain networks, endocrine status, and risk genotypes in patients with newly diagnosed prostate cancer referred to androgen‐deprivation therapy
Autor: | Simon Buus, Robert Zachariae, Cecilie R. Buskbjerg, S. M. Hadi Hosseini, L. Haldbo-Classen, Claus Højbjerg Gravholt, Ali Amidi |
---|---|
Rok vydání: | 2020 |
Předmět: |
Male
Risk neuropsychological tests Oncology Apolipoprotein E Cancer Research medicine.medical_specialty Genotype Neuropsychological Tests Catechol O-Methyltransferase prostatic neoplasms Androgen deprivation therapy 03 medical and health sciences Prostate cancer Apolipoproteins E 0302 clinical medicine cognitive dysfunction Internal medicine medicine Humans Cognitive Dysfunction Testosterone Patient Reported Outcome Measures Prospective Studies 030212 general & internal medicine Effects of sleep deprivation on cognitive performance brain-derived neurotrophic factor (BDNF) Aged apolipoprotein ε (APOE) medicine.diagnostic_test business.industry Brain-Derived Neurotrophic Factor connectome Neuropsychology Brain Prostatic Neoplasms Cancer Androgen Antagonists Neuropsychological test medicine.disease catechol-O-methyltransferase (COMT) Diffusion Magnetic Resonance Imaging Case-Control Studies 030220 oncology & carcinogenesis testosterone business Blood sampling |
Zdroj: | R. Buskbjerg, C, Zachariae, R, Buus, S, H. Gravholt, C, Haldbo-Classen, L, Hosseini, S M H & Amidi, A 2021, ' Cognitive impairment and associations with structural brain networks, endocrine status, and risk genotypes in patients with newly diagnosed prostate cancer referred to androgen-deprivation therapy ', Cancer, vol. 127, no. 9, pp. 1495-1506 . https://doi.org/10.1002/cncr.33387 |
ISSN: | 1097-0142 0008-543X |
Popis: | Background: Evidence suggests that patients with prostate cancer (PCPs) receiving androgen-deprivation therapy (ADT) are at risk for cognitive impairment. Research with other populations with cancer indicates that cognitive impairment may also occur before systemic treatment. The authors assessed cognitive impairment in untreated PCPs referred to ADT and explored associations with structural brain networks, endocrine status, and selected genotypes. Methods: Forty untreated PCPs and 27 healthy controls (HCs) who completed a questionnaire package underwent neuropsychological testing, magnetic resonance imaging, and blood sampling. Cognitive impairment was defined as a z score ≤−2 on 1 neuropsychological test or ≤−1.5 on 2 neuropsychological tests. Structural brain networks were investigated using diffusion-weighted imaging and graph theory. Associations of cognitive performance with patient-reported outcome measures (PROMs), brain networks, testosterone levels, and genotypes (apolipoprotein ε [APOE], catechol-O-methyltransferase [COMT], and brain-derived neurotrophic factor [BDNF]) were explored. Results: PCPs performed poorer than HCs on 7 of 15 neuropsychological tests and exhibited a higher frequency of cognitive impairment (57.5% vs 22.2%; P ≤.01 to.03). All neuropsychological outcomes were associated with ≥1 PROM (P ≤.01 to.04). Compared with the HC group, the PCP group exhibited altered global network organization as well as disrupted regional network characteristics in frontal and temporal regions (P |
Databáze: | OpenAIRE |
Externí odkaz: |